1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Silence Therapeutics plc (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Silence Therapeutics plc (Silence Therapeutics), formerly SR Pharma plc, is a biotechnology company. It discovers, develops and delivers RNA interference (RNAi) therapeutics for the treatment of serious diseases. The company's pipeline products include Atu027 (AtuPLEX/PKN-3) for pancreatic, head and neck cancer and Atu111 (DACC/Ang-2) for lung indications. It also develops products in partnership which includes PF-655 for diabetic macular edema and wet age related macular degeneration and QPI 1002 for kidnet transplantation. Silence Therapeutics works in partnership with pharmaceutical and biotechnology companies and academic research institutions. Some of the key partners of the company include AstraZeneca, Pfizer and Quark Pharma, and Dainippon Sumitomo to further enhance its RNAi therapeutic developments. It has operations in the US and Germany. Silence Therapeutics is headquartered in London, the UK.

Silence Therapeutics plc (RTRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

Table Of Contents

Silence Therapeutics plc (RTRX) - Pharmaceuticals and Healthcare - Deals and Alliances Profile
Table of Contents


Table of Contents 2

List of Tables
3

List of Figures
4
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Silence Therapeutics plc, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deal Details 11
Venture Financing 11
Intradigm Secures Additional US$2.9 Million In Series B Financing 11
Partnerships 12
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies 12
Silence Therapeutics Extends RandD Collaboration With AstraZeneca 13
Silence Therapeutics Extends Co-Development Agreement With AstraZeneca 14
Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma 15
Silence Therapeutics Enters Into Agreement With Dainippon Sumitomo Pharma 16
Licensing Agreements 17
Silence Therapeutics Terminates Licensing Agreement With University Of Massachusetts 17
Equity Offering 18
Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million 18
Silence Therapeutics Completes Private Placement Of Shares For US$29 Million 19
Silence Therapeutics Completes Private Placement Of Shares For US$8 Million 21
Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million 23
Silence Therapeutics Completes Private Placement Of Shares For US$7 Million 24
Silence Therapeutics Announces Private Placement Of Shares For US$16 Million 26
Silence Therapeutics Completes Private Placement Of US$9 Million 27
Silence Therapeutics Completes Public Offering Of US$0.71 Million 29
Silence Therapeutics Completes Private Placement Of US$24 Million 31
Silence Therapeutics Completes Private Placement Of US$4.05 Million 33
Acquisition 35
Silence Therapeutics Completes Acquisition Of Intradigm 35
Silence Therapeutics plc - Key Competitors 38
Key Employees 39
Locations And Subsidiaries 40
Head Office 40
Other Locations and Subsidiaries 40
Appendix 41
Methodology 41
About GlobalData 41
Contact Us 41
Disclaimer 41


List of Tables

Silence Therapeutics plc, Pharmaceuticals and Healthcare, Key Facts, 2013 1
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Silence Therapeutics plc, Pharmaceuticals and Healthcare Deals By Type, 2009 to YTD 2015 6
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Silence Therapeutics plc, Deals By Therapy Area, 2009 to YTD 2015 8
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals Summary, 2009 to YTD 2015 9
Intradigm Secures Additional US$2.9 Million In Series B Financing 11
Silence Therapeutics Enters Into Co-Development Agreement With InteRNA Technologies 12
Silence Therapeutics Extends RandD Collaboration With AstraZeneca 13
Silence Therapeutics Extends Co-Development Agreement With AstraZeneca 14
Silence Therapeutics Expands Its Collaboration With Dainippon Sumitomo Pharma 15
Silence Therapeutics Enters Into Agreement With Dainippon Sumitomo Pharma 16
Silence Therapeutics Terminates Licensing Agreement With University Of Massachusetts 17
Silence Therapeutics Announces Private Placement Of Shares For US$16.8 Million 18
Silence Therapeutics Completes Private Placement Of Shares For US$29 Million 19
Silence Therapeutics Completes Private Placement Of Shares For US$8 Million 21
Silence Therapeutics Completes Rights Offering Of Shares For US$0.39 Million 23
Silence Therapeutics Completes Private Placement Of Shares For US$7 Million 24
Silence Therapeutics Announces Private Placement Of Shares For US$16 Million 26
Silence Therapeutics Completes Private Placement Of US$9 Million 27
Silence Therapeutics Completes Public Offering Of US$0.71 Million 29
Silence Therapeutics Completes Private Placement Of US$24 Million 31
Silence Therapeutics Completes Private Placement Of US$4.05 Million 33
Silence Therapeutics Completes Acquisition Of Intradigm 35
Silence Therapeutics plc, Key Competitors 38
Silence Therapeutics plc, Key Employees 39
Silence Therapeutics plc, Other Locations 40
Silence Therapeutics plc, Subsidiaries 40


List of Figures

Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 1
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 1
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 1
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 1
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Year, 2009 to YTD 2015 5
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals by Type, 2009 to YTD 2015 6
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Region, 2009 to YTD 2015 7
Silence Therapeutics plc, Pharmaceuticals and Healthcare, Deals By Therapy Area, 2009 to YTD 2015 8

Companies Mentioned

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Ahmad

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.